Clinical Pharmacologists Warn of DTC Genomics Backlash on PGx
By GenomeWeb,
GenomeWeb News
| 07. 22. 2009
The American College of Clinical Pharmacy has called for federal oversight of direct-to-consumer genetic testing companies, which it believes could inadvertently hold back advances in clinical pharmacogenetic and pharmacogenomic testing.
In a position statement published in the Journal of Clinical Pharmacology, ACCP argued that consumer response to genetic testing advertising could have "both immediate and long-term effects on public health and the future adoption of pharmacogenetic/genomic testing."
The paper explains that consumers could be let down or confused by the performance of DTC genetic tests, which could have a negative impact on other genetic testing firms that do not market directly to consumers.
The ACCP likened consumer ads for genetic tests to those for prescription drugs, which are regulated by the US Food and Drug Administration's Division of Drug Marketing, Advertising, and Communications. The group noted that a similar oversight system is not yet in place for the young genetic testing field.
"Given the rate of development of genetic testing and its widespread availability and accessibility by the public, the establishment of effective governmental oversight needs to be undertaken...
Related Articles
By Josie Ensor, The Times | 12.09.2025
A fertility start-up that promises to screen embryos to give would-be parents their “best baby” has come under fire for a “misuse of science”.
Nucleus Genomics describes its mission as “IVF for genetic optimisation”, offering advanced embryo testing that allows...
By Hannah Devlin, The Guardian | 12.06.2025
Couples undergoing IVF in the UK are exploiting an apparent legal loophole to rank their embryos based on genetic predictions of IQ, height and health, the Guardian has learned.
The controversial screening technique, which scores embryos based on their DNA...
By Frankie Fattorini, Pharmaceutical Technology | 12.02.2025
Próspera, a charter city on Roatán island in Honduras, hosts two biotechs working to combat ageing through gene therapy, as the organisation behind the city advertises its “flexible” regulatory jurisdiction to attract more developers.
In 2021, Minicircle set up a...
By Vardit Ravitsky, The Hastings Center | 12.04.2025
Embryo testing is advancing fast—but how far is too far? How and where do we draw the line between preventing disease and selecting for “desirable” traits? What are the ethical implications for parents, children, clinicians, and society at large? These...
